S1P/S1P受体通路:炎症性肠病治疗新靶点的研究进展  

S1P/S1P Receptor Pathway:A New Target for Treatment of Inflammatory Bowel Disease

作　　者：张克慧 李勇[1] ZHANG Kehui;LI Yong(Department of Gastroenterology,Shanghai Municipal Hospital of Traditional Chinese Medicine,Shanghai 200071)

机构地区：[1]上海市中医医院脾胃病科,200071

出　　处：《胃肠病学》2023年第1期57-61,共5页Chinese Journal of Gastroenterology

基　　金：国家自然科学基金(81873157);2023年度上海中医药大学科技发展项目(23KFL091);未来计划中医药科技发展项目(WL-HBQN-2022006K)。

摘　　要：目前,开发可以稳定治疗炎症性肠病(IBD)的靶向口服药物仍是一个临床待解决的难题。近年来有研究证实,鞘氨醇-1-磷酸(S1P)/S1P受体通路可以调节淋巴细胞归巢和免疫调控,抑制肠道炎症,保护肠道内皮屏障,并对肠道微生物代谢产生影响,可能在IBD治疗中发挥关键作用。本文就S1P/S1P受体通路对IBD的影响及其潜在的作用机制作一综述。The development of targeted oral drugs that can stably treat inflammatory bowel disease(IBD)is still a clinical problem to be solved.In recent years,studies have confirmed that sphingosine-1-phosphate(S1P)/S1P receptor pathway can regulate lymphocyte homing and immune regulation,inhibit intestinal inflammation,protect intestinal endothelial barrier,and affect intestinal microbial metabolism,which may play a key role in the treatment of IBD.This article reviewed the effect of S1P/S1P receptor pathway on IBD and its potential mechanism.

关 键 词：炎症性肠病 S1P/S1P受体 治疗 淋巴细胞归巢 免疫调节 肠道微生物 

分 类 号：R574[医药卫生—消化系统]